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CHAPTER ONE
REVIEW OF THE LITERATURE
Human Immunodeficiency Virus I
Human Immunodeficiency Virus type 1 (HIV-1) was first discovered to cause Acquired
Immune Deficiency Syndrome (AIDS) in 1983 and since then, continues to be a serious health
issue in many parts of the world, particularly Sub-Saharan Africa and the Americas (26).
Historically about 35 million people have died resulting in an HIV related illness and 70 million
people have been infected with the virus. Today, an estimated 36.7 million people are living
with HIV, with approximately 2.1 million new cases annually (27).
HIV-1 is known to infect CD4+ T cells, macrophages and microglial cells of the immune
system. Both CD4+ T cells and macrophages express the CD4 molecule on their cell surface, as
well as the chemokine receptor CCR5, both of which are utilized by HIV-1 for cellular entry. Viral
binding and entry is the first step in the viral lifecycle (4, 5). The sequential binding of viral
protein gp120 to both CD4 and CCR5 initiates fusion of the virus and plasma membranes, as the
virus is brought in close proximity to the target cell. Following fusion, the viral core trafficks
through the cytoplasm, during which time the virus begins reverse transcribing its RNA genome
into the double stranded DNA form that it ultimately integrated into the host cell genome via
the viral protein Integrase (4, 5). Upon integration, transcription results in the early synthesis of
regulatory HIV-1 proteins, of which assist in generating longer RNA transcripts. Subsequently,
1

these newly structured proteins are assembled at the cell surface and released as a new,
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mature virion following its budding from the host cell plasma membrane (4, 5).
The pathogenesis of HIV-1 infection is a consequence of both the infecting virus, as well
as the host’s immune response to the virus. Viral transmission requires direct exposure and is
highly dependent on the virus isolate, its concentration and host susceptibility. CD4+ T cells are
the first to become infected, spreading the virus into the regional lymph nodes and
subsequently into the bloodstream (4, 5). Viral replication is at its height during this acute
phase of the primary infection; virus particles can be found in dendritic cells, CD4+ T cells and
macrophages. Infected cells typically succumb to the infection, undergoing cell death or
establishing a form of latent infection. During this stage of infection, the number of CD4+ T cells
dramatically declines as viral titers rapidly increase, yet this response is short lived as the host
generates humoral and cellular immune responses (4, 5). Upon Antibody-Dependent Cellular
Cytotoxicity, mediated by Natural Killer T cells and HIV-specific T cells and antibodies, HIV-1
RNA levels decline and CD4+ T cells raise again, although never fully recovering from the
persistent infection. The HIV-1 pathogenic effects persist, albeit asymptomatic, resulting in the
progressive loss of CD4+ T cells and viral spread within the lymphoid environments. In the
absence of treatment, patients develop AIDS and typically succumb to opportunistic infections
due to their weakened immune system (Figure 1).
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Figure 1. Treatment-Naïve HIV-1 Time Course. A schematic of treatment-naive HIV-1 infection time
course in which viral RNA copies are represented in red and CD4+ T cell count in blue. HIV-1 RNA copies
are steadily increasing, while CD4+ T cells are rapidly declining during the stage of primary infection. As
time progresses latent reservoirs are established resulting in clinical latency. With a lack of treatment,
opportunistic infections arise and HIV-1 disease will progress into AIDS.

In the past 20 years, HIV-1 infection has transitioned from a life-limiting disease often
met with fatal opportunistic infections to a manageable chronic infection with a near-normal
life span and few opportunistic infections. This transition has been made possible through four
major advancements both in the patient care, as well as scientific research advancements
including: gaining a better understanding of HIV-1 replication and the subsequent relationship
of immunological and clinical progression, the development and utilization of combination
antiretroviral therapy (CART), the ability to optimize patient treatment via reliable
measurements of CD4+ helper T cells, plasma HIV-1 RNA levels and antiretroviral resistance
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profiles, and lastly the shift of treatment with beginning CART upon HIV-1 infection and patient
commitment regardless of CD4+ T cell count (26, 27).
CART works to limit HIV-1 viral replication through inhibition of multiple stages in the
HIV-1 life cycle (Figure 2). Specifically, nucleoside and nucleotide reverse transcriptase
inhibitors suppress viral replication, integrase inhibitors work by blocking the incorporation of
the viral genome into host DNA, and protease inhibitors prevent the proteolytic cleavage of
protein precursors required for the production of viral particles (4, 5). Combination therapies
are advantageous in that they greatly decrease the risk of the evolution of drug-resistant
strains. Unfortunately, in 2016 it was estimated that only 17 million, or about 46% of the 36.7
million individuals living with HIV-1, were actually receiving CART (26, 27).
While CART has significantly reduced the mortality associated with HIV-1, these
therapies are unable to completely eradicate the infection. This is because HIV-1 is capable of
establishing latency, primarily within infected CD4+ T cells, creating what are known as latent
reservoirs throughout the body (4, 5). If CART is stopped or temporarily interrupted, the virus
can rapidly rebound, viral replication will resume and lead to AIDS if treatment is not resumed.
Furthermore, patients on CART are at an increased risk for a number of inflammatory
complications, including, cardiovascular disease, renal complications and HIV-Associated
Neurocognitive Disorders.
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Figure 2. HIV-1 Time Course Following CART Treatment. A schematic of HIV-1 disease progression with
introduction to CART, in which CD4+ T cell count and HIV-1 RNA levels are depicted against treatment timeline.
CD4+ T cells are rapidly declining, while HIV-1 RNA copies are steadily increasing prior to CART introduction.
Once treatment begins, CD4+ T cell count recovers, while measurable HIV-1 RNA levels are at a steady decline.
(Adapted from Rohrbach, J., et al.)

HIV-Associated Neurocognitive Disorders
Prior to treatment options which were not introduced into the mid-1990s, HIVassociated dementia (HAD) was relatively common affecting at least 20 percent of HIV-1
infected individuals. HAD is the most severe form of cognitive impairment associated with
infection and is described as, “marked cognitive impairment involving at least two cognitive
domains that substantially interferes with daily functioning” (23, p. 234). Almost always fatal,
HAD has substantially declined since the use of CART and is now rare in the developed world.
Still, CART compliant HIV-1 positive individuals experience a spectrum of neurocognitive,
behavioral and motor dysfunctions, decreasing their quality of life. Collectively, these infection-

associated inflammatory complications are known as HAND, or HIV-Associated Neurocognitive
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Disorders, and its neuropathogensis remains an important unresolved issue (1-3, 23).
Historically, encephalitis and neuronal loss were thought to play a central role in the
pathogenesis of HAD yet these pathologies are no longer typical, therefore no longer sufficient
in providing an explanation of the neurological dysfunction in the CART era. The continuation of
HAND pathology, despite viral treatment plans, suggest an underlying pathophysiology more
likely associated with the functional alterations in neurons (7, 8).
Neurological involvement and changes in brain structure occurs very rapidly after
infection; within the first few months following infection, reductions in brain volume, decreases
in white matter and increased permeability of the blood-brain barrier have been observed.
Moreover, an increase in circulating levels of inflammatory cytokines, acute metabolic
disturbances, and immune activation accompany measurable deficits in cognitive and
psychomotor functions (7, 8). Unfortunately, many of these modifications do not improve and
even have been shown to worsen over time following the initiation of CART, although systemic
viral suppression has been achieved.
The relative inaccessibility of the affected brain tissue hinders our understanding of the
pathogenic mechanisms underlying HAND; although, contemporary pathological studies of
CART-treated individuals report unfavorable changes in white matter integrity, with clear signs
of inflammation and neuronal damage (7, 8). This neuronal dysfunction may be due to a
number of infected cells such as perivascular macrophages, astrocytes and microglia via a range
of mechanisms poorly defined. CART-compliant patients have limited brain-localized HIV-1
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replication suggesting that HAND is not the sole consequence of viral replication but may be the
result of viral protein expression in infected glial cells which are able to induce toxicity and
death of nearby neuronal cells (23, 31). Early and progressive disturbances of bioenergetics, as
well as, evidence for abnormal glutamate homeostasis have been implicated in the cause of
neuronal injury and death (23). A model proposed by Saylor et al., outline the possible
neuropathogenic mechanisms that contribute to HAND:
HIV-infected macrophages and microglial cells release neurotoxic viral proteins that
trigger astrocyte activations, which results in increased glutamate release and reduced
glutamate uptake. Elevated extracellular glutamate levels cause neuronal bioenergetic
disturbances that lead to aberrant synaptodendritic pruning and neuronal injury. Moreover,
systemic inflammation and microbial translocation products lead to microglial activation and
increased production of chemokines and cytokines that contribute to neuronal injury (23, p.
240).
Extracellular Vesicles and HIV-Associated Neurocognitive Disorders
To date, the mechanism by which HIV-1 infected monocytes induce neurotoxicity to
neighboring cells is unknown, although a number of studies suggest extracellular vesicles may
be responsible (12-14, 16, 17, 34). Extracellular vesicles packaged with pathological proteins,
such as amyloid beta and alpha-synuclein, have been shown to induce pathology in neighboring
neuronal cells of neurodegenerative diseases including Alzheimer’s and Parkinson’s,
respectively (6, 15, 18, 21). Furthermore, there is emerging evidence that HIV-1 infected cells
induce the release of extracellular vesicles containing viral RNA, microRNA and viral proteins
resulting in the altered gene expression and other pathological consequences in neighboring
cells exposed to these extracellular vesicles. This extracellular vesicle-mediated neurotoxicity
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may be the source of neuropathology in HAND (12-14, 16, 17, 34). If so, neurotoxic extracellular
vesicles may contribute to HAND symptoms in CART treated patients who continue to present a
significant reduction or even minimal levels of ongoing viral replication. As such, it is possible
that the role of extracellular vesicles in HAND is similar to their role in other, above mentioned,
neurodegenerative diseases. There are a number of HIV-1 RNA and proteins that have been
implicated in the neuropathological spread HAND, yet this study will focus on three HIV-1
proteins, Nef, Tat and Vpr, which have been implicated in the progression of HAND, and are
known to be associated with extracellular vesicles.
Nef, or Negative Regulatory Factor, is a 27-34 kDa myristoylated protein involved in
multiple functions during the replication cycle of HIV (22). Nef is known to increase viral
infectivity through various actions such as activation of T cell signaling pathways, promoting
particle release, causing CD4 receptor down modulation and anti apoptotic signaling (9, 10).
This HIV-1 protein consists of a N-terminal myristoyl (14-carbon) lipid attached to the second
glycine reside and many positive charges in the first 22 amino acids, constituting Nef as a
membrane-associated protein (22).
Nef expression occurs early during HIV-1 infection of CD4+ T cells, macrophages and
astrocytes, and has been known to be released form these cells as a cargo protein in
extracellular vesicles (9,10). Neurotoxic effects of Nef including neurological degeneration,
cytokine production and negative alterations in cellular pathways were discovered using
recombinant Nef on human glial cells and neurons. Moreover, animal studies in rats exhibited
HIV-1 Nef-induced neurocognitive impairments (89). Lastly, a recent study performed by
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Saribas et al., concluded that HIV-1 Nef is released in extracellular vesicles derived from primary
human astrocytes and that these vesicles are taken up by primary human neurons, causing
axonal and neurite degeneration (88).
The HIV-1 protein Tat, or Trans-Activator of Transcription, consists of 86-101 amino
acids depending on the subtype and has been suggested as a causative agent in HAND due to
its neuroexcitatory and neurotoxic abilities (11). Being one of the three early encoded proteins,
Tat is required for viral replication through its interaction with its response element of the HIV1 long terminal repeat, allowing for the phosphorylation of RNA polymerase II thus resulting in
the synthesis of HIV-RNA transcripts (11). Furthermore, Tat has been shown to be released by
HIV-1 infected CD4+ T cells and taken up by uninfected “bystander” T cells directly resulting in
cellular apoptosis. It has been hypothesized that due to its lack of signal sequence, Tat may
follow an unconventional secretory pathway allowing for its release (90).
Tat is transported across the blood brain barrier by systemic circulation, secreted by
infected macrophages and microglia, and has been detected in brain of patients with HAND. Tat
has also been associated with extracellular vesicles released from HIV-1 infected CD4+ T cells
and when applied to neurons, results such as shorter or no visible neurites and significant
neuronal cell death became apparent (90). These results suggest that extracellular vesicle
associated Tat is biologically active. Furthermore, a recent study described by Hui et al.,
concluded that Tat was found to induce significant neuronal cell death from 48 hours of
treatment, with a maximum death rate of 50% after 96 hours. After incubation of Tat with
neurons, Tat was found to be compartmentalized in endolysosomes; moreover, significant size

increases and aggregation of endolysosomes was observed (90). Interestingly, autophagic
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dysfunctions have been implicated in the pathogenesis of HAND and Tat treated neurons have
been shown to have decreased levels of pro-autophagic proteins, and increased levels of
autophagic inhibitory proteins (90).
The Viral Protein R, or Vpr, is a 14 kDa protein which induces G2 cycle arrest and causes
apoptosis in proliferating cells (30, 32). In the context of macrophages, Vpr has been known to
interact with molecular pathways resulting in the sequestration of proinflammatory
transcriptional activators causing immunosuppression, thus allowing for the establishment and
maintenance of a systemic infection. Vpr has been identified to modify host cell energy
metabolism, proteasome function, and oxidative status, yet while this protein has been
extensively studied in the context of HIV-1 infection, the precise mechanism of action remains
enigmatic (91).
Recently James et al. described VPR as having a, “unique role in neuropathogensis” and
that through extracellular vesicle based intercellular communication VPR has deleterious
effects (30, p. 409). Furthermore, VPR was found among the extracellular vesicle population
released from HIV-1 infected lymphocytic cells in a study published by Li et al. in 2013 (31).
Extracellular Vesicle Formation
Originally thought to be the cell’s disposal mechanism of discarding unwanted materials,
extracellular vesicles have, in the last twenty years, become a topic of interest as they have
been implicated in various cellular processes such as cell proliferation, differentiation, death
and cellular immune responses (33, 34). A look into the cargo of extracellular vesicles allows for
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the presumption that these proteins, nucleic acids, miRNAs, and other cargoes are specifically
and intentionally packaged into extracellular vesicles, rather than representing “trash”
packaged for the removal from the cell. Extracellular vesicles, ranging in size from 30 to 1000
nm, are often categorized based on size into more precise populations such as exosomes,
microvesicles, ectosomes or apoptotic bodies; for the purpose of study I will continue to utilize
the inclusive term “extracellular vesicles”.
Extracellular vesicles may be the result of secretion directly from the plasma membrane,
released following the endocytic pathway, or can be the product of autophagic unconventional
secretion (19, 20, 56-58). The biogenesis of extracellular vesicles released directly from the
plasma membrane are the result of outward budding and fission of the plasma membrane. A
number of events will allow for their release, such as the redistribution of phospholipids,
contraction of actin-myosin machinery or a calcium influx and hypoxia, to name a few (24, 25,
28). A more detailed cascade of events allowing for extracellular release directly from the
plasma membrane includes the activation of phospholipase D via ADP-ribosylation factor 6 this,
in turn, allows for the recruitment of extracellular signal-regulated kinase (ERK). ERK
phosphorylates, thereby activating the myosin light chain kinase, triggering the release of
extracellular vesicles (24, 25, 28).
Endosomes are clatherin-coated vesicles located within cells and can be derived either
from the exocytic or endocytic pathways (25, 49, 54, 85). Endosomes can be further classified
into early, late, or recycling endosomes. Early endosomes are the first to receive incoming cargo
and fluid, they have a highly dynamic structure with a high propensity to undergo homotypic

fusion. Early endosomes mature into either the recycling endosome transferring cargo to the
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plasma membrane, or the late endosome resulting in the enrichment of tetraspanins and often
a large accumulation of intraluminal vesicles (ILVs) (25, 49, 54, 85). The formation of ILVs, as
well as the protein incorporation into ILVs, is driven by a number of proteins together known as
the endosomal sorting complexes required for transport (ESCRT). Upon acquiring multiple ILVs,
the late endosome can also be referred to as a multivesicular body (MVB). Often, the late
endosome/MVB fuses with the lysosome resulting in degradation; however, a separate fate is
fusion with the plasma membrane, giving way to extracellular vesicle release as the late
endosome/MVB releases it’s ILVs into the extracellular milieu (25, 49, 54, 85).
Extracellular vesicles as a product of autophagic unconventional secretion is a multistep
process, involving a number of distinct and dynamic membrane compartments. The exact
mechanisms and pathways responsible for autophagic unconventional secretion are unknown,
yet is thought to play a role in the secretion of cytosolic cargo of which lack signals of export.
Autophagic secretion begins with the process of macroautophagy whereby elongation of a
double membrane, or phagophore, is initiated via the ATG1/ULK1 complex (66, 70, 75). While
sequestering cytosolic cargos, the phagophore matures into the double-membrane vesicle
known as the autophagosome, driven by the lipidation of the LC3 protein. This autophagosome
continues in maturation, accumulating a number of ILVs, possibly fusing with other nearby
MVBs to form what is known as the amphisome (66, 70, 75). This amphisome can follow one of
two fates: fusion with the lysosome in which enclosed cargo meets degradative enzymes such
as glycosidases, proteases and sulfatases, or fusion with the plasma membrane resulting in the

release of the amphisome’s ILVs as extracellular vesicles (66, 70, 75, 82-84). Interestingly, the
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idea that the two pathways are underway suggest that different subpopulations of ILVs exist
simultaneously within cells, one population destined for degradation, the other released as
extracellular vesicles.
Tetraspanins Give Way to Extracellular Vesicle Biogenesis
Tetraspanins belong to a conserved transmembrane family of glycoproteins typically
consisting of 200-300 amino acids (28, 29, 45). Often tetraspanins act as scaffolding proteins,
anchoring multiple proteins to one area of the plasma membrane in what as known as a cluster
of differentiation (CD); CDs have been shown to be a successful tool for in the
immunophenotyping of a variety of cell types, as well as extracellular vesicles. Kowal et al.,
propose the differential separation of extracellular vesicles via immuno-isolation using CD9,
CD63 and CD81 in hopes of allowing a, “proper evaluation of the molecular mechanisms of
biogenesis and secretion and the respective functions of subtypes of extracellular vesicles” (28,
p. 969).
Ranging from 25-65 kDa, due to post-translational glycosylation, CD63 was the first
characterized tetraspanin (45). This ubiquitously expressed protein is localized within the
endosomal system and the cell surface. Most often associated with the late endosome/MVB
and lysosome, CD63 consists of a particular consensus motif required for endocytosis at the
plasma membrane and has also been implicated in direct lysosomal targeting (45). CD63 is
approximately seven times as enriched in the ILVs of the MVB, when compare to the

endosomal limiting membrane. Interestingly, incorporation of CD63 into the ILVs seems to be

14

independent of the ESCRT machinery (45).
CD9 is a 24 kDa tetraspanin and is reported to exhibit both promigratory and
antimigratory properties via integrin-dependent signaling (29). Associated with the plasma
membrane, CD9 has been implicated in muscle cell fusion, as well as egg-sperm fusion.
Interestingly, CD9 is often associated or in complex with CD81, a 26 kDa cell surface
tetraspanin; their association has been implicated in tumor cell behaviors such as motility via
ligand attachments and breast cancer cell morphology (29). Alone, CD81 plays a significant role
in cell attachment/entry of Hepatitis C, the pathogenesis of the Plasmodium species, as well as
the virion assembly and release of HIV-1 (28, 29).

CHAPTER TWO
NOVEL APPROACHES TO ANALYZING SINGLE EXTRACELLULAR VESICLES
Rather than assuming homogeneity within the extracellular vesicle population, we
hypothesize that distinct populations of extracellular vesicles are released, and that
environmental conditions can alter this population. Previous work in the field has examined
these extracellular vesicles in bulk, examining western blots of cellular protein or RNA levels
present in all collected extracellular vesicles via RT-PCR, from a given cell population. To
determine the heterogeneity of the populations, I aim to evaluate the populations of secreted
extracellular vesicles at the single vesicle level. By creating new methodologies for studying
single extracellular vesicles, this allows for a more thorough understanding of their suspected
involvement in a variety of pathologies such as HAND.
In order to concentrate the extracellular vesicle population differential centrifugation
was utilized in this study, although there are various methods of extracellular vesicle
purification including immunomagnetic isolation methods, ultrafiltration methods, or sucrose
gradient fractionation methods. Yet, as each method has its challenges we have decided to
employ the the “gold standard” of purification methods, of which is the most common among
vesicle research to date (92).
Using techniques successful in studying virions, I have similarly incorporated fluorescent
markers into secreted extracellular vesicles by fusing a fluorophore such as GFP, to the first 15
15
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amino acids of the Src protein (S15); this provides the foundation of plasma membrane
incorporation due to the particular positive charge and propensity to undergo a myristoylation
reaction. The first 15 amino acids of the Src protein undergo a myristoylation reaction at the
second Glycine reside from the N-terminal, acting as a plasma membrane anchor. Furthermore,
with its high number of arginines and lysines, this particular stretch of basic amino acids
increases Src’s propensity for the plasma membrane. This S15 membrane marker has been
shown to incorporate throughout the plasma membrane, fluorescently tag budding virions
from the plasma membrane and now has been successful in providing a fluorescent marker of
secreted extracellular vesicles. Following cellular expression of the S15 construct, released
extracellular vesicles can be analyzed through protein co-localization analysis with the
utilization of the canonical vesicle markers CD9, CD63 and CD81, as well as lysosomal marker
LAMP1 and TSG101. Quantification via wide-field deconvolution microscopy combined with
imaging software, allows for the analysis of extracellular vesicles at a single vesicle level.
Because of its uniformity and sensitivity, wide field deconvolution microscopy is an ideal
tool to quantify the fluorescent intensity of extracellular vesicle populations. For an unbiased,
high throughput analysis algorithms are generated utilizing Bitplane Imaris imaging software to
create three dimensional surfaces around individual extracellular vesicles (Figure 3). For
example, surfaces are created around the S15-GFP membrane marker and the fluorescence
intensity of other, co-localized markers such as the tetraspanin CD63 or LAMP1 within these
individual S15 surfaces, are exported as individual events for analysis. In this way, it is possible

to analyze and compare large quantities of extracellular vesicles containing the S15-GFP and
Immunofluorescent markers to determine their heterogeneous nature.

Figure 3. Representative Sample of Surface Masks. The left panel shows an
example of an acquired image in one fluorescent channel of interest. Surface
algorithms are generated to detect puncta within various parameters.
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CHAPTER THREE
OVERALL HYPOTHESIS AND EXPERIMENTAL GOALS
The pathways of extracellular vesicle communication and their selective cargoes can
become hijacked in the context of many diseases, including viral infection, thus contributing to
the pathogenesis of HAND. In HIV-1 positive patients undergoing CART, viremia is potently
suppressed, preventing the development of AIDS. However, these CART-suppressed individuals
still exhibit non-AIDS disease states such as HAND, which include neurological disorders with
varying severity. Current literature suggests that extracellular vesicles may be involved in the
pathogenesis of HAND in the CNS as they are believed to be transferring HIV-1 proteins,
including Tat, Nef and Vpr, to nearby neuronal cells. Overall, I hypothesize that extracellular
vesicles containing HIV-1 proteins are of a heterogeneous population. By achieving a better
understanding of the molecular and cellular mechanisms which lead to the pathology of HAND
in HIV-1 patients, therapeutic interventions can become a possibility.
To begin addressing the pathogenesis of HAND in the CNS, a foundation of study must
be established and primitive questions must first be addressed. Ultimately analyzing
extracellular vesicles derived from HIV-1 infected cells is most applicable in a disease-state
model, yet to analyze the population of extracellular vesicles released following HIV-1 infection
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would require a reliable method of separating virus from extracellular vesicles. Physical and
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chemical characteristics, as well as biogenesis pathways are almost identical between
extracellular vesicles and virions causing an analysis such as this very challenging. In a
foundational study such as this the main focus is to validate a method of single vesicle analysis,
as well as just begin the study of vesicle populations containing HIV-1 proteins.
Through the achievement of two experimental goals, I hope to better understand
populations of extracellular vesicles containing HIV-1 proteins and approach the answers to
some of the following questions. Do extracellular vesicles contain HIV-1 proteins Tat, Nef or
Vpr? Are these vesicles similar to one another? Can we decipher the possible biogenesis of
subsets of extracellular vesicle populations? Will the canonical biomarkers CD9, CD63 and
CD81provide useful information of these extracellular vesicles? Will LAMP1 or TSG101 allow us
to draw conclusions of their biogenesis?
Experimental Goal: Determine if distinct populations of extracellular vesicles are
released within and among cell types. Through the developed method previously described in
Chapter Two, I aim to analyze extracellular vesicle populations at the single vesicle level. The
common vesicle markers CD9, CD81 and CD63, as well as LAMP1 and TSG101, will be utilized to
characterize populations based on their co-localization analyses. Assessment at the level of a
single vesicle will shed light on their heterogeneity and begin unique analysis of their suspected
involvement in a variety cellular processes.
Experimental Goal: Define the cell surface markers of extracellular vesicles containing
HIV-1 proteins relevant to HAND. Following the validation of single extracellular vesicle analysis,
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I aim to determine if/how HIV-1 viral protein expression, specifically Tat, Nef or Vpr, influences
the quantity and quality of extracellular vesicle populations. Again, the common vesicle markers
CD9, CD81 and CD63, as well as LAMP1 and TSG101, will be utilized to characterize these
populations of particular interest. Simultaneous assessment of these markers on thousands of
extracellular vesicles will allow a previously unachieved appreciation for the specific vesicle
populations produced before and after HIV-1 viral protein expression.

CHAPTER FOUR
DISTINCT POPULATIONS OF EXTRACELLULAR VESICLES ARE RELEASED WITHIN AND
AMONG CELL TYPES
Materials and Methods
Cell Culture.
HEK 293T (293T) cells were cultured at 37 degrees Celsius and 5 percent Carbon Dioxide
in Dulbecco’s modified Eagle’s Medium (DMEM) containing phenol red (Invitrogen),
supplemented with the addition of 10 percent fetal bovine serum (FBS) (Hyclone), 100 IU/ml
penicillin, 100 ug/ml streptomycin and 10 ug/ml ciprofloxacin hydrochloride.
Mesenchymal Stem Cells (MSCs) were cultured at 37 degrees Celsius and 5 percent
Carbon Dioxide in Iscvoe’s Modified Dulbecco Minimum Essential Medium (IDMEM) containing
phenol red (Invitrogen), supplemented with the addition of 10 percent fetal bovine serum (FBS)
(Hyclone), 10 percent horse serum (Hyclone), 100 IU/ml penicillin, 100 ug/ml streptomycin and
10 ug/ml ciprofloxacin hydrochloride.
Transfection of S15 GFP Construct and Extracellular Vesicle Collection.
293T cells were transfected at approximately 60 percent confluency using
Polyethylenimine (PEI), with equal parts of psPax2 and S15-GFP plasmids. Cell supernatant was
collected 48, 72 and 96 hours post-transfection for extracellular vesicle collection via
differential ultracentrifugation. For the vesicle collection, collected supernatant was first spun
21

at 4,000g for 20 minutes, 10,000g for 30 minutes and 100,000g for 70 minutes. The pelleted
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vesicles were then re-suspended in PBS and spun at 100,000g for 70 minutes. All differential
centrifugation was performed in 4 degrees Celsius. Concentrated extracellular vesicle pellets
were re-suspended in PBS and stored at -80 Celsius.
Immunofluorescent Staining.
For extracellular vesicle visualization experiments, collected vesicles were spinoculated
onto glass coverslips at 13 degrees Celsius for 2 hours at 1200g and subsequently fixed with a
solution consisting of 0.1 M PIPES and 3.7 percent formaldehyde (Polysciences) for 5 minutes.
Following fixation, vesicles were incubated with the following possible primary antibodies at a
concentration of 1:1000: mouse anti-CD9 (BD Pharmigen), mouse anti-CD63 (BD Pharmigen),
mouse anti-CD81 (BD Pharmigen), or mouse anti-TSG101 (Santa Cruz Biotechnology Inc.) along
with the rabbit anti-Lamp1 antibody (Abcam), in a PBS block solution supplemented with 10
percent normal donkey serum (NDS), and 0.01 percent NaN3 for 1 hour. Following primary
antibody incubation vesicles were incubated with their respective secondary antibody
conjugated to a fluorophore, either donkey anti-mouse 594-conjugated or donkey anti-rabbit
647-conjugated, at a concentration of 1:400, for 20 minutes in the same, above described PBS
block solution.
Wide-Field Deconvolution Microscopy and Analysis.
Extracellular vesicle images were taken on a DeltaVision wide field fluorescent
microscope (Applied Precision, GE) outfitted with a digital camera (CoolSNAP HQ;

Photometrics), while using a 1.4 numerical aperture, and 60 X objective lens. The acquired
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images were deconvolved with the SoftWoRx deconvolution software (Applied Precision) and
analyzed on Bitplane: Imaris software version 7.6.4.
Puncta were analyzed for vesicle-like characteristics, such as size and sphericity, and a
surface algorithm was built around the S15-GFP signal. The maximum fluorescence intensity
found within these puncta was then analyzed and cross analyzed with the other perspective
channels. Finally, all acquired images were subjected to the same algorithm via the Batch
Coordinator tool (Bitplane) to each respective signal. All statistical analyses and graphs were
created using GraphPad Prism version 5.00 or 6.00 (GraphPad Software, Inc.).
Results and Conclusions
To validate the proposed methodology of single vesicle analysis, extracellular vesicles
derived from transfected S15-GFP 293T cells were analyzed following collection,
immunofluorescent staining, and wide-field deconvolution microscopy. Results following the
CD63/LAMP1 protein co-localization analysis reveal the vesicle population as heterogeneous;
whereby, only 4.2 percent of S15-GFP positive puncta are also positive for CD63 and LAMP1.
Furthermore, S15-GFP 293T vesicles are more likely to be CD63 positive, rather than LAMP1
positive, as CD63 positive puncta account for 41.5 percent, as opposed to the 1.0 percent found
to be positive for LAMP1. Interestingly, a large proportion of S15 positive 293T extracellular
vesicles, 53.3 percent, are negative for both LAMP1 and CD63.

S15-GFP 293T extracellular vesicle co-localization analysis with surface markers CD81
and LAMP1 reveal similar results in that a small percentage, 3.5 percent, are LAMP1 positive.
This population of extracellular vesicles are more likely to be CD81 positive, revealing a 51.2
percent positive expression profile, and 12.3 percent positive for both LAMP1 and CD81.
Similarly, this analysis reveals a significant proportion of S15-GFP extracellular vesicles are
negative for either CD81 or LAMP1, 33.0 percent.
293T S15-GFP EXTRACELULAR VESICLES
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Figure 4. 293T Extracellular Vesicle Analysis. Here, we are depicting the colocation of the S15-GFP surface
marker with either LAMP1 and CD63, or LAMP1 and CD81. Dot plots are sectioned into quadrants with
corresponding percentages. The upper right quadrant quantifies the triple positive puncta, whereas the lower left
quadrant quantifies the S15-GFP positive puncta alone. Bar graphs represent the summation of each quadrant,
accounting for 100 percent of the S15-GFP positive puncta.
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Following analysis of S15-293T extracellular vesicles and determining that the
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methodology utilized for individual vesicle analysis has been successful, it was of interest to
examine another cell type to determine if the vesicle populations are distinct from one another.
Extracellular vesicles derived from GFP MSCs were analyzed for their protein co-localization,
with the same canonical markers utilized in characterizing S15-GFP 293T extracellular vesicles.
Interestingly, the protein profile derived from GFP MSC extracellular vesicles was very
unique, in comparison to the S15-GFP 293T derived vesicles. Extracellular vesicles derived from
GFP MSCs had a high propensity for LAMP1, and showed much lower levels of the tetraspanin
protein markers CD63 and CD81. Again, this analysis reveals a significant proportion of GFP MSC
extracellular vesicles are negative for either CD81 or LAMP1, 30.5 percent, and negative for
either CD61 or LAMP1, 51.2 percent.
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Figure 5. MSC Extracellular Vesicle Analysis. Here we are depicting the colocalization of the MSC GFP surface
marker with either CD81 and LAMP1, or CD63 and LAMP1. Dot plots and bar graphs are arranged in the same
manner as described in Figure 4.

Overall, when comparing the vesicle populations of S15-GFP 293T and GFP MSCs, it is
apparent that 293T extracellular vesicles have a much higher overall intensity level than the
MSCs in GFP expression, CD63 and CD81 tetraspanin expression. Interestingly, intensity of
LAMP1 differ in that the MSC extracellular vesicles have a much higher expression profile, than
their 293T counterpart. Figure 6 depicts the comparison analysis of max intensity of each
individual puncta, analyzed from within their own channel surface mask. Worth observing is the

puncta count from each channel surface mask; not always are the most intense puncta the

27

most populous.
Although, it must be addressed that the conjugate antibody of tetraspanins CD63 and
CD81 are from mouse; therefore, these data must be taken lightly as MSCs are derived from
mice. Fortunately, the LAMP1 conjugate antibody is against rabbit allowing the data to be fully
interpreted as presented.

Cell Type EV Max Intensity Comparison
Analysis
95,101
113,700

125,088

204,263
66,090

26,136
79,338

110,850

Figure 6. Cell Type EV Max Intensity Comparison
Here, we are comparing the fluorophore signal intensity of all puncta from each
surface mask created. The red numbers represent the total puncta number.
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Figure 7: Extracellular Vesicle Protein Co-Localization Analysis. This data shows the summation of both
S15-GFP 293T and GFP MSC vesicle co-localization analyses with either CD81, LAMP1, CD81 and LAMP1
(top), or CD63, LAMP1, or CD63 and LAMP1 (bottom). Bar graphs represent the summation of each
protein co-localization analysis, with corresponding colors.

CHAPTER FIVE
CELL SURFACE MARKERS OF EXTRACELLULAR VESICLES CONTAINING HIV-1 PROTEINS RELEVANT
TO HAND
Materials and Methods
Cell Culture.
HEK 293T (293T) cells were cultured at 37 degrees Celsius and 5 percent Carbon Dioxide
in Dulbecco’s modified Eagle’s Medium (DMEM) containing phenol red (Invitrogen),
supplemented with the addition of 10 percent fetal bovine serum (FBS) (Hyclone), 100 IU/ml
penicillin, 100 ug/ml streptomycin and 10 ug/ml ciprofloxacin hydrochloride.
THP-1 cells were cultured at 37 degrees Celsius and 5 percent Carbon Dioxide in Roswell
Park Memorial Institute medium (RPMI) containing phenol red (Invitrogen), supplemented with
the addition of 10 percent fetal bovine serum (FBS) (Hyclone), 100 IU/ml penicillin, 100 ug/ml
streptomycin and 10 ug/ml ciprofloxacin hydrochloride.
Protein-GFP Fusion Constructs.
Expression plasmids encoding HIV-1 proteins Nef, Tat and Vpr were generated by PCR–
based strategy. First, HIV-1 viral proteins Tat and Nef were fused to the N-terminus of GFP in a
pEGFP-N1 backbone (Figure 7B, 7C). Following this, the Tat-GFP fused protein was subcloned
into the multiple cloning site of the lentiviral backbone (pLVX) by PCR-based strategy (Figure
7A).
29

Transfection of Protein-GFP Constructs and Generation of Stable TAT-GFP Cell Line.
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293T cells were transfected at approximately 60 percent confluency using
Polyethylenimine (PEI), with either the NEF-GFP-N1, TAT-GFP-N1 or GFP-VPR plasmid. Cell
supernatant was collected 48, 72 and 96 hours post-transfection for extracellular vesicle
collection via differential ultracentrifugation.
Lentivirus for transduction was produced by transfection of 293T cells with equal parts
of vesicular stomatitis virus glycoprotein (VSV-G), packaging construct psPax2, and Tat-GFPpLVX. Viruses were harvested 48 hours post-transfection, filtered through a 0.45-µm filter
(Millipore), and used to transduce THP-1 cells. Cells were selected 48 hours post-transduction in
RPMI containing 5 µg/ml puromycin (Sigma-Aldrich).
Extracellular Vesicle Collection.
Collected supernatant was first spun at 4,000g for 20 minutes, 10,000g for 30 minutes
and 100,000g for 70 minutes. The pelleted vesicles were then re-suspended in PBS and spun at
100,000g for 70 minutes. All differential centrifugation was performed in 4 degrees Celsius.
Concentrated extracellular vesicle pellets were re-suspended in PBS and stored at -80 Celsius.
Immunofluorescent Staining.
For extracellular vesicle visualization experiments, collected vesicles were spinoculated
onto glass coverslips at 13 degrees Celsius for 2 hours at 1200g and subsequently fixed with a
solution consisting of 0.1 M PIPES and 3.7 percent formaldehyde (Polysciences) for 5 minutes.
Following fixation, vesicles were incubated with the following possible primary antibodies at a

concentration of 1:1000: mouse anti-CD9 (BD Pharmigen), mouse anti-CD63 (BD Pharmigen),
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mouse anti-CD81 (BD Pharmigen), or mouse anti-TSG101 (Santa Cruz Biotechnology Inc.) along
with the rabbit anti-Lamp1 antibody (Abcam), in a PBS block solution supplemented with 10
percent normal donkey serum (NDS), and 0.01 percent NaN3 for 1 hour. Following primary
antibody incubation vesicles were incubated with their respective secondary antibody
conjugated to a fluorophore, either donkey anti-mouse 594-conjugated or donkey anti-rabbit
647-conjugated, at a concentration of 1:400, for 20 minutes in the same, above described PBS
block solution.
Wide-Field Deconvolution Microscopy and Analysis.
Extracellular vesicle images were taken on a DeltaVision wide field fluorescent
microscope (Applied Precision, GE) outfitted with a digital camera (CoolSNAP HQ;
Photometrics), while using a 1.4 numerical aperture, and 60 X objective lens. The acquired
images were deconvolved with the SoftWoRx deconvolution software (Applied Precision) and
analyzed on Bitplane: Imaris software version 7.6.4.
Puncta were analyzed for vesicle-like characteristics, such as size and sphericity, and a
surface algorithm was built around the GFP signal. The maximum fluorescence intensity found
within these puncta was then analyzed and cross analyzed with the other perspective channels.
Finally, all acquired images were subjected to the same algorithm via the Batch
Coordinator tool (Bitplane) to each respective signal. All statistical analyses and graphs were
created using GraphPad Prism version 5.00 or 6.00 (GraphPad Software, Inc.).

Results and Conclusions
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Extracellular vesicles may be the result of secretion directly from the plasma membrane,
released following the endocytic pathway, or can be the product of autophagic unconventional
secretion (19, 20, 56-58). Nef extracellular vesicles are less than 5 percent LAMP1 positive
leading us to believe that Nef may be secreted directly from the plasma membrane, as LAMP1
is associated with autophagic unconventional secretion. These data correlate well with the
structural model of Nef, as this protein consists of an N-terminal myristoylation, causing Nef to
be a membrane-associated protein (Figure 9C). Furthermore, the previously described S15-GFP
membrane marker, consisting of a myristoylated glycine residue and positive charges, reveal a
similar co-localization analysis with LAMP1 at approximately 5 percent. Lastly, the extracellular
vesicles of Nef colocalize more so with the tetraspanins CD63 and CD81, of which are known to
be located in the plasma membrane of cells, rather than the late endosome/MVB tetraspanin
CD9.
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Figure 8. Agarose Gel Electrophoresis of Generated HIV-1 Protein Plasmids.
Panel A depicts the Tat-GFP-pLVX clone. Panel B depicts the Tat-pEGFP-N1
clone. Panel C depicts the Nef-pEGFP-N1 clone.

Figure 9. Representative Example of Triple Co-Localization. Panel A is a portion of the total image achieved of
which three distinct channels are visible. Panel B reveals a number of surfaces which have been created to
detect puncta within the parameters of the set algorithm. Triple colocalization can be detected in panel C, from
each individual fluorescent channel: NEF-GFP (D), CD9 (E) and LAMP1(F).
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Figure 10. 293T Nef-GFP Extracellular Vesicle Protein Co-Localization Analyses and Protein Structure. (A) This
data shows the summation of each Nef-GFP antibody stain; each protein co-localization analysis has 3 total
data replicates. Error bars show the standard error of the mean. (B) Bar graphs to represent the summation of
each protein co-localization analysis. (C) Structural example of HIV-1 protein Nef.

Unlike Nef extracellular vesicles, Tat profiles are nearing 20 percent positive for LAMP1,
suggesting their release is more associated with the autophagic unconventional secretion
pathway. Yet, as the data present Tat often colocalizes with CD63 and CD81 as well suggesting
their release directly from the plasma membrane. Although confounding, these Tat single
vesicle analyses may lead to the conclusion that this particular HIV-1 protein is packaged and
released within vesicles from multiple, or more than one pathway.
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Figure 11. 293T Tat-GFP Extracellular Vesicle Protein Co-Localization. This data shows the summation of each
Tat-GFP antibody stain; each protein co-localization analysis has 3 total data replicates. Error bars show the
standard error of the mean. Bar graphs to represent the summation of each protein co-localization analysis.

Similar to extracellular vesicles released from Tat-GFP 293T cells, Tat-GFP THP-1
extracellular vesicles are nearing 20 percent positive for LAMP1, yet expression of tetraspanins
CD9, CD63, CD81 and ESCRT protein TSG101 have all decreased. Possibly THP-1 Tat vesicles are
associated with the autophagic unconventional secretion pathway.
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Figure 12. THP-1 Tat-GFP Extracellular Vesicle Protein Co-Localization. This data shows the summation of
each Tat-GFP antibody stain; each protein co-localization analysis has 3 total data replicates. Error bars show
the standard error of the mean. Bar graphs to represent the summation of each protein co-localization
analysis.

Extracellular vesicles released from GFP-Vpr expressing 293T cells present with a protein
co-localization profile more similar to 293T Tat-GFP vesicles, than 293T Nef-GFP vesicles. As the
data present, Vpr vesicles are nearing 25 percent positive for LAMP1, suggesting their release
are more associated with the autophagic unconventional secretion pathway. Of the three HIV-1
protein expressing extracellular vesicle populations, Vpr vesicles have the lowest co-localization
with the tetraspanins CD9, CD63 and CD81, yet the highest expression of ESCRT protein
TSG101, suggesting that Vpr vesicles may be derived from an unconventional secretion
pathway as TSG101 is a protein found within late endosomes/MVB.
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Figure 13. 293T GFP-Vpr Extracellular Vesicle Protein Co-Localization. This data shows the summation of each
GFP-Vpr antibody stain; each protein co-localization analysis has 3 total data replicates. Error bars show the
standard error of the mean. Bar graphs to represent the summation of each protein co-localization analysis.

CHAPTER SIX
DISCUSSION
Extracellular vesicle analysis at the level of individual vesicles provides a newfound
appreciation of their heterogeneous population, allowing for further analysis of possible
subpopulations. Prior to this work the techniques most often utilized to study extracellular
vesicles were based on the entire population, via western blot or RT-PCR, constraining
viewpoints of homogeneity. The validated methodology provided in this study has the potential
to be utilized in the examination of various extracellular vesicles released from any set of cells,
under a variety of treatment options, allowing a broader understanding of extracellular vesicles.
Moreover, through the use of various protein markers such as tetraspanins CD9, CD63 and
CD81, as well as ESCRT protein TSG101 and lysosomal marker LAMP1, it may be possible to
determine the biogenesis of extracellular vesicles implicated in HAND pathogenesis.
Immunofluorescent staining and wide-field deconvolution microscopy coupled with canonical
vesicle markers allows for the analysis of subpopulations of extracellular vesicles released into
the extracellular milieu.
Results from this study revealed that distinct vesicles are released within and among cell
types. The S15-GFP membrane-associated marker was the way in which extracellular vesicles
were visualized for further analysis. It was found that S15-GFP 293T vesicles were less than 5
percent LAMP1 positive and were significantly more positive for tetraspanins CD63 or CD81
38

suggesting their release to be generated directly from the plasma membrane or the classic,
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exocytic pathway of extracellular biogenesis rather than an unconventional autophagic
secretion. This data correlates well with the membrane-association of the S15-GFP marker, yet
through our analyses it became apparent that not all extracellular vesicles were S15-GFP
positive (especially those that were LAMP1 positive) leading us to believe that it would be
beneficial to study extracellular vesicle populations with a more inclusive marker. Possibly
membrane-intercalating fluorescent dyes would be a more appropriate tool in the analysis of
entire extracellular populations.
This methodology of single vesicle analysis was then applied to a second cell type, MSCs
as they were readily available. GFP MSC extracellular vesicles had a unique protein colocalization profile, being much more LAMP1 positive compared to the S15-GFP extracellular
vesicles released from 293T cells. Interestingly, MSCs have been shown to have extremely high
autophagosome concentration even during basal state which correlates with the data
presented here (19). Their profile of tetraspanins CD63 and CD81, are insignificant among the
vesicle population, yet as stated previously this may be due, in part, to the fact that the primary
antibody for these tetraspanins were against mouse of which MSCs are derived. It would be of
interest to analyze MSC extracellular vesicles with the appropriate species type antibodies to
determine their true tetraspanin profile.
The extracellular vesicle analyses containing HIV-1 proteins relevant to HAND display
the possibility of utilizing this technique of extracellular vesicle analysis within vesicle
populations implicated in pathogenesis. HIV-1 proteins Tat, Nef and Vpr were of interest due to

their broad association in HAND, as well as their incorporation into extracellular vesicle
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populations. The majority of these studies were carried out with the utilization of 293T cells,
allowing for the foundation of single vesicle analysis with the incorporation of HIV-1 proteins.
As might be expected it would be of great interest to continue such analyses in more relevant
cell types, such as THP-1 cells differentiated into macrophages; these cells would bring us one
step closer to the CNS resident microglia.
Extracellular vesicles derived from cells over-expressing GFP fusions to each of these
proteins of interest, present with unique protein co-localization analyses. The population of
Nef-GFP extracellular vesicles was found to be highly associated with tetraspanins CD63 and
CD81 and less so with CD9, TSG101 and LAMP1. These data fall in line with the structure of Nef,
as myristoylation allows for plasma membrane association, much like the S15-GFP membrane
marker. It would be of great interest to determine if other, more HIV-1 applicable cell lines such
as THP-1 cells, have similar extracellular vesicle characterizations. Unfortunately for this study
time did not permit those analyses.
In comparison, Tat-GFP vesicles, both derived from 293T and THP-1 cells, are more
inclined to be positive for all markers including tetraspanins CD9, CD63 and CD81, TSG101, and
LAMP1. Quite possibly Tat protein is released within multiple vesicle populations, derived from
various biogenesis pathways, as literature suggests states of disease and alterations of cellular
metabolism perturb the cells natural extracellular vesicle biogenesis pathways (6, 15, 18, 21).
Tat, a protein known to be often secreted from HIV-1 infected cells, may incorporate itself into
many extracellular populations for means of exiting the cell.

Lastly, GFP-Vpr extracellular vesicles present with the highest expression of ESCRT
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protein TSG101; this suggests that their release may be more connected to the classic, exocytic
pathway of extracellular biogenesis as TSG101, an ESCRT protein, is often found within late
endosomes/MVB. With hopes of studying this viral protein in a more relevant HIV-1 disease
model cell line, THP-1 cells were generated to express GFP-Vpr via transduction. Unfortunately,
these cells were unable to thrive as the Vpr protein is known to cause G2 cycle arrest. A
doxycycline-inducible system was of interest, as it would potentially allow for limited
expression of Vpr, yet despite many attempts it was regrettably unsuccessful during this study.
After analyzing obtained data it became apparent that although various markers were
utilized with the goal of characterizing the whole extracellular vesicle populations, a large
proportion of vesicles were negative for any of the chosen markers. This limitation is possibly
the result of surface algorithms created to detect positive puncta. Such algorithms created for
each channel of interest have been applied to thousands of extracellular vesicles with
background levels derived from the secondary antibody only controls. Quite possibly during the
analysis, the detection methods utilized were too conservative excluding positive puncta.
Alternatively, is would be of interest to include a broader range of both integral, as well as
transmembrane proteins for further characterization of the extracellular vesicle population.
Perhaps, the inclusion of heat shock proteins or membrane transport proteins may better
reveal the true characteristics of all extracellular vesicles obtained.
In future studies involving extracellular vesicles containing HIV-1 proteins, it would be
revealing to expose neuronal cell lines to each extracellular vesicle population individually (Nef,

Tat, or Vpr) to determine their deleterious effects. Quite possibly one protein is more
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neurotoxic than the next or even one pathway of extracellular vesicle biogenesis produces
more neurotoxic vesicles. To begin to address the latter, future studies may utilize various
pharmacological treatments to inhibit one or more extracellular vesicle biogenesis pathways.
For instance, Bafilomycin A1 may be utilized to inhibit the production of lysosomes or MG132
to perturb the formation of autophagosome, thus altering pathways of cellular degradation and
vesicle biogenesis.
Additionally, it would be meaningful to determine how prevalent Nef, Tat or Vpr are
among the entire vesicle population released from HIV-1 infected cells. Possibly as a result of
HIV-1 infection, the extracellular vesicle populations are altered even more so than during the
single protein expression induced here. To analyze the population of extracellular vesicles
released following HIV-1 infection would require a reliable method of separating virus from
extracellular vesicles. Physical and chemical characteristics, as well as biogenesis pathways are
almost identical between extracellular vesicles and virions causing an analysis such as this very
challenging.
In this thesis of, THE NOVEL CHARACTERIZATION OF EXTRACELLULAR VESICLES
CONTAINING PROTEINS WHICH HAVE BEEN IMPLICATED IN THE PATHOGENESIS OF HIV
ASSOICIATED NEUROCOGNITIVE DISORDERS we have shown that extracellular vesicles
containing HIV-1 proteins are not of a homogeneous population. Through the utilization of
canonical markers and wide-field deconvolution microscopy we can analyze the larger
population at the single vesicle level to determine their possible mode of biogenesis. This study
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provides the foundation in characterizing and better understanding extracellular vesicles which
may be responsible for the pathogenesis of a multitude of neuropathological disorders.
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